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REVIEWImproving predictions of the risk of resistance development against new
and old antibioticsD. I. Andersson
Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, SwedenAbstractThe methods used today by academic researchers and the pharmaceutical industry to assess the risk of emergence of resistance, for example
during development of new antibiotics or when assessing an old antibiotic, are sub-optimal. Even though easy to perform, the presently used
serial passage procedures, minimal prevention concentration measurements and determination of mutation rates in vitro are generally
providing inadequate knowledge for risk assessment and making decisions to continue/discontinue drug development. These methods
need to be complemented and replaced with more relevant methods such as determination of whether resistance genes already pre-exist
in various metagenomes, and the likelihood that these genes can transfer into the relevant pathogens and be stably maintained.
Furthermore, to determine the risk of emergence of mutationally conferred resistance the ﬁtness effect of the resistance mechanism is
key, as this parameter will determine the ability of the resistant mutants to be maintained and enriched in the host after they have
emerged. This information combined with knowledge of bacterial population sizes and growth and killing dynamics at relevant infection
sites should allow for better forecasting of the risk of resistance emerging in clinical settings.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
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E-mail: Dan.Andersson@imbim.uu.seMethods Used Today for Prediction of
ResistanceDuring the development of new antibiotics or the revival of old
antibiotics, predicting the risk of resistance (in the context of
this paper resistance is not deﬁned with regard to clinical break
points but only refers to reduced susceptibility in comparison
to a wild-type population) has become an increasingly more
important part of the drug development process for both ac-
ademic researchers and pharmaceutical companies. As a result,
there has been an increasing interest in developing risk
assessment methods, and a low rate of mutational resistance
development in vitro has become a more crucial characteristic in
the development and promotion of new hits and leads [1]. ToMicrobiol Infect 2015; 21: 894–898
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.012predict mutational resistance in the laboratory a rather limited
set of methods are usually used [2]. These include ﬁrst, classical
serial passage experiments at progressively increasing concen-
trations of antibiotic to determine if and how rapidly resistant
mutants appear and how high a level of resistance is achievable,
and second, determination of the mutant prevention concen-
tration. The second method is determined by plating a deﬁned
number of cells (typically 1010) on increasing antibiotic con-
centrations to determine at which concentrations no mutants
appear, i.e. the mutant prevention concentration [3,4]. This
method then provides a measure of the drug concentration
needed to prevent the selection of a ﬁrst-step mutant that
occurs with a rate of approximately >10−10 per cell per gen-
eration. Neither of these methods is used to determine an
actual mutation rate, but instead they provide qualitative an-
swers (serial passage) or threshold values (mutant prevention
concentration). To obtain mutation rates a third method, the
classical Luria–Delbruck ﬂuctuation tests, is used where many
independent bacterial cultures are grown, and cells from each
culture are plated on various drug concentrations to determineious Diseases. Published by Elsevier Ltd. All rights reserved
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advantage of this method is that an actual mutation rate is
determined that can subsequently be related to the bacterial
population size and a calculated probability of emergence and
ﬁxation of resistant mutants.Limitations of Existing MethodsThere are at least two reasons why resistance prediction based
on the above methods alone (as is often done) is at best of
limited value and at worst misleading. The ﬁrst reason is that
the majority of resistance mechanisms observed in today’s
pathogens are conferred by horizontal gene transfer (HGT) of
pre-existing resistance genes, and obviously in vitro measure-
ments of the likelihood of mutational resistance cannot give any
information about the risk of HGT. The horizontally trans-
ferred resistance genes usually encode proteins that modify the
drug or the target, and that were transferred ready-made to the
pathogen. These resistance genes are part of the so-called
resistome (the collection of all antibiotic resistance genes and
their precursors present in bacteria) and many of those found
in pathogens are thought to have their origin in various envi-
ronmental bacteria [5,6]. For example, the widespread and
clinically very problematic CTX-M class of genes was probably
imported to pathogens from different species of the environ-
mental genus Kluyvera [7–9]. This example also illustrates the
importance of the presence of a genetic element (insertion
sequence ISEcp1) that probably allowed mobilization of the
progenitor resistance gene from Klyuvera into other species
[10]. Similarly, the plasmid-encoded qnrA gene was most likely
transferred from Shewanella algae into various Enter-
obacteriaceae species [11]. Another relevant example is pro-
vided by the tetX gene, which is likely to have its immediate
origin in Bacteroides fragilis [12,13]. A recent study in a Sierra
Leone hospital showed that 21% of Gram-negative bacteria (e.g.
Escherichia coli, Klebsiella pneumoniae and Enterobacter sp.) iso-
lated from urine carried the tetX gene, demonstrating that
resistance genes can rapidly enter into human pathogens from
other bacteria [14].
The second reason for why the presently used methods are
inadequate regards mutational resistance, and it is based on the
probability that resistant mutants pre-exist in the infecting
bacterial population. Mutation rates determined in vitro against
our presently available and clinically used repertoire of anti-
biotics span at least six logs (from about 10−11 to 10−5 per cell
per generation) when selection occurs at drug concentrations
substantially above MIC for the susceptible wild-type strains.
Examples of mutation rates include the following: in the lowerClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyrange, 10−11 to 10−10 for oxazolidinones in Staphylococcus
aureus [15]; in the intermediate range, 10−9 for rifampicin in
E. coli [16], and in the higher range, 10−5 for mecillinam in E. coli
[17]. Even though this million-fold variation in mutation rate is
observed in in vitro experiments, the rate by which resistance
appears in patients during treatment is not correlated to these
rates in any obvious way. That is, a very high mutation rate, for
example, as for mecillinam (10−5 per cell per generation) does
not necessarily translate into fast resistance development in a
treated patient, as indicated by the fact that resistance to
mecillinam has remained relatively low among clinical isolates
[18,19]. Conversely a low mutation rate to resistance in vitro
does not necessarily mean slow resistance evolution, as indi-
cated by, for example, streptomycin resistance (10−10 per cell
per generation) in Mycobacterium tuberculosis and linezolid
resistance in S. aureus (10−11 per cell per generation) where
resistance was almost immediately observed after these drugs
were introduced for clinical use [20–22]. This would imply
that for the majority of pathogens and infections the proba-
bility of ﬁxation of a resistant mutant is not strongly limited by
the mutation rate per se. A likely reason for this is that within
the range of mutation rates (10−11 to 10−5) and population
sizes observed for most infections, pre-existing resistant
mutant are almost always present. In other words, the muta-
tion supply rate (population size × mutation rate) is much
greater than 1.
The above reasoning suggests that knowledge about bacterial
population sizes is essential for better predictions of the
emergence of mutational resistance. Population sizes within an
infected host are often not known, but in cases where they are
known they are generally large enough such that with the
typical mutation rates discussed above (even the lowest ones),
resistant mutants would be present in the population at any
given time-point. For example, for urinary tract infections
(UTIs) the population sizes during infection range from 104
bacteria/mL (the population size threshold for a UTI) [23] up to
108, resulting in total population sizes (with a full bladder of
300 mL) approaching 1010 per bladder for a major infection. In
respiratory and wound infections (in rodent models) the
number of bacteria can exceed 1010 per gram of tissue [24] and
for pulmonary tuberculosis infections in humans there can be
105–106 bacteria/mL of sputum [25] and even higher [26,27] in
necrotic zones and caseous material. Furthermore, in patients
with meningitis and bronchitis the bacterial counts can reach up
to 109/mL [28,29]. Hence, these numbers would suggest that
the total bacterial population size in an infected individual is
typically >1010, implying that with the observed mutation rates
pre-existing resistant mutants are in most cases expected to be
present when treatment is initiated.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 894–898
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TransferA comprehensive prediction for a new antibiotic ﬁrst needs to
include a determination of whether resistance genes are already
pre-existing somewhere in the resistome, in particular in en-
vironments where pathogens and environmental bacteria are
likely to transiently meet or co-exist. Even though the meth-
odology to determine this by functional genomics is relatively
straightforward— involving cloning of random DNA pieces
obtained from various complex metagenomes (e.g. from soil
bacteria or human/animal commensals) into an expression
plasmid, transfer into the relevant pathogen and screening for
phenotypic resistance to the antibacterial of interest— these
types of experiments are rarely performed and reported in the
literature for new antibiotic candidates. Second, if resistance
genes are indeed found, the risk for HGT of the genes into the
relevant pathogens needs to be assessed. This prediction is
more difﬁcult to perform as it depends on several parameters
that are generally poorly deﬁned. Hence, the probability of
HGT will depend on ecological opportunity (i.e. the extent of
contact between potential donor bacterium and pathogen),
in vivo HGT rates between different species, the likelihood of
ﬁxation of the transferred DNA and functional gene expres-
sion. In spite of these difﬁculties, it is today possible to make
informed risk evaluations based on experiments. Hence, HGT
rates as well as the probability of ﬁxation of a novel genetic
element and its expression can be experimentally measured and
used for an estimation of risk of transfer.Improved Methods to Measure the Risk of
Emergence of Mutational ResistanceGenerally the ﬁtness of the resistant mutant and the infection
dynamics are more relevant parameters to assess than the rate
by which resistant mutants emerge. An illustration of this
reasoning is provided by two cases where mutation rates and the
rate of evolution of resistance during treatment lack correlation.
The ﬁrst example is given by results obtained from studies of the
antibiotics mecillinam, fosfomycin and nitrofurantoin, all of which
are used to treat uncomplicated UTIs. The in vitro mutation rate
for resistance to these drugs is in the higher range, approximately
10−7 to 10−5 per cell per generation, and a priori one would as-
sume that resistance to these antibiotics should rapidly emerge.
Hence, with bacterial population sizes in the bladder up to about
109–1010 mathematical modelling results suggest that treatment
failure due to the presence of pre-existing resistant mutants
would be very common [17,30–32]. However, the use of theseClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdrugs for uncomplicated UTIs is rarely associated with devel-
opment of resistance during treatment, even though the ex-
pected number of resistant mutants present in the population
might be as high as 105 (population size 1010 × mutation rate
10−5) when treatment is initiated. The lack of enrichment of this
resistant sub-population and resulting treatment failure can be
explained by the ﬁtness costs associated with the resistance
mechanisms and the particular dynamics of the bladder envi-
ronment. Hence, with continuous production of urine and
micturition the bacteria need to grow above a certain rate to be
maintained in the bladder (at least in the planktonic phase). In
other words, even though the resistant mutants continuously
appear at a high rate they cannot be enriched and ﬁxed because
they grow too slowly in the presence of drug to be maintained in
the bladder during regular micturition [17,31,32]. One predic-
tion from this argument is that if these antibiotics were to be
used for other types of infections, such as pneumonia and sep-
ticaemia [33,34], where the population dynamics is different and
the demand for fast bacterial growth is not as stringent as in a
UTI, resistance development is expected to be faster (assuming
similar drug exposure at the different infection sites). In the
example discussed above, the particular dynamics of the bladder
(regular micturition) imposes a demand for sufﬁciently fast
growth of the resistant sub-population to allow its maintenance
in the infected host. This reasoning could be extended also to the
immune system, where its killing effect on bacteria would reduce
the probability that a newly emerging resistant mutant will
become enriched and ﬁxed in response to antibiotic exposure.
Hence, it is expected that the risk of mutational resistance
development for the same bacterial agent and antibiotic is higher
at an infection site with a low rate of immunological killing of
bacteria compared with a high turnover site.
A second and contrasting example to the UTIs discussed
above is provided by the evolution of resistance in
M. tuberculosis-infected patients given streptomycin mono-
therapy in the late 1940s. The mutation rate to streptomycin
resistance (due to a few rRNA and rpsL point mutations) is in the
order of 10−10 per cell and generation (about 105-fold lower
than for mecillinam), implying that resistance development
should be slow. However, in many of these patients resistant
mutants were rapidly selected (within 1–2 months after initia-
tion of treatment), which concomitantly resulted in treatment
failure [20]. This fast resistance evolution probably occurred
because (i) the M. tuberculosis population is generally large
enough (n >1/mutation rate) to contain pre-existing mutants
[25–27]; (ii) the ﬁtness cost of resistance is relatively small [35];
and (iii) the rate of immunological killing and turnover of the
bacterial population is low at the infection sites (at least in
comparison to a UTI). Hence, when contrasting the UTI and
tuberculosis examples it is obvious that per se the in vitroious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 894–898
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risk. Instead, pathogen-speciﬁc ﬁtness costs and infection dy-
namics are more important parameters to measure for a rele-
vant risk prediction. During recent years a wide repertoire of
in vitro and in vivomethods have been developed that allow ﬁtness
costs to be measured under a number of different conditions
[36,37]. Likewise, bacterial growth/killing rates in relevant
infection models can be experimentally determined, allowing
assessment of the likelihood that a resistant mutant emerges by
mutation and ﬁxes in response to a speciﬁc selective pressure.ConclusionsInstead of relying on inadequate mutation rate determinations,
improved resistance predictions need to incorporate HGT rates
and the ﬁtness costs of the particular resistance mechanisms in
the relevant infection model. In addition, knowledge of the dy-
namics of the infection and the bacterial population size are
equally important to allow for a realistic risk prediction of
resistance evolution by mutation during treatment. In light of the
dryness of the pipeline of new antibiotics and the high costs
associated with drug development, it is even more important
that stop/go decisions for a new compound in development, or
the reintroduction of an old antibiotic, is based on relevant
experimental data with regard to assessing the future risk of
resistance evolution. If not, we might not only discard a prom-
ising antibiotic because we erroneously assume that a high in vitro
mutation rate to resistance results in fast resistance develop-
ment in a treated patient, but conversely we might also make
unnecessary investments in a drug because we mistakenly
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